| Title: | Haploinsufficiency of ITSN1 is associated with a substantial increased risk of Parkinson's disease |
| Journal: | Cell Reports |
| Published: | 7 Mar 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/40056900/ |
| DOI: | https://doi.org/10.1016/j.celrep.2025.115355 |
| Title: | Haploinsufficiency of ITSN1 is associated with a substantial increased risk of Parkinson's disease |
| Journal: | Cell Reports |
| Published: | 7 Mar 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/40056900/ |
| DOI: | https://doi.org/10.1016/j.celrep.2025.115355 |
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Despite its significant heritability, the genetic basis of Parkinson's disease (PD) remains incompletely understood. Here, in analyzing whole-genome sequence data from 3,809 PD cases and 247,101 controls in the UK Biobank, we discover that protein-truncating variants in ITSN1 confer a substantially increased risk of PD (p = 6.1 × 10-7; odds ratio [95% confidence interval] = 10.5 [5.2, 21.3]). We replicate this association in three independent datasets totaling 8,407 cases and 413,432 controls (combined p = 4.5 × 10-12). Notably, ITSN1 haploinsufficiency has also been associated with autism spectrum disorder, suggesting variable penetrance/expressivity. In Drosophila, we find that loss of the ITSN1 ortholog Dap160 exacerbates α-synuclein-induced neuronal toxicity and motor deficits, and in vitro assays further suggest a physical interaction between ITSN1 and α-synuclein. These results firmly establish ITSN1 as a PD risk gene with an effect size exceeding previously established loci, implicate vesicular trafficking dysfunction in PD pathogenesis, and potentially open new avenues for therapeutic development.</p>
| Application ID | Title |
|---|---|
| 26041 | Large-Scale Sequencing in the UK Biobank to Facilitate Gene Discovery, Genome Sciences, and Precision Medicine |
| 68601 | Large-scale whole genome sequencing of the UK Biobank cohort to generate and evaluate therapeutic hypotheses regarding targets, biomarkers and pathways implicated in disease |
Enabling scientific discoveries that improve human health